Artivion Inc (AORT)

$21.06

+0.28

(+1.35%)▲

Live

Insights on Artivion Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 87.85M → 93.67M (in $), with an average increase of 6.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -9.80M → -3.97M (in $), with an average increase of 146.6% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 61.5% return, outperforming this stock by 70.9%

Performance

  • $20.53
    $21.18
    $21.06
    downward going graph

    2.52%

    Downside

    Day's Volatility :3.05%

    Upside

    0.54%

    downward going graph
  • $12.16
    $21.90
    $21.06
    downward going graph

    42.26%

    Downside

    52 Weeks Volatility :44.47%

    Upside

    3.84%

    downward going graph

Returns

PeriodArtivion IncSector (Health Care)Index (Russel 2000)
3 Months
23.03%
1.9%
0.0%
6 Months
57.42%
10.7%
0.0%
1 Year
47.69%
4.6%
-1.1%
3 Years
-12.14%
14.2%
-22.1%

Highlights

Market Capitalization
847.5M
Book Value
$6.86
Earnings Per Share (EPS)
-0.75
PEG Ratio
420.83
Wall Street Target Price
24.08
Profit Margin
-8.67%
Operating Margin TTM
5.17%
Return On Assets TTM
1.21%
Return On Equity TTM
-10.84%
Revenue TTM
354.0M
Revenue Per Share TTM
8.69
Quarterly Revenue Growth YOY
18.0%
Gross Profit TTM
202.5M
EBITDA
38.1M
Diluted Eps TTM
-0.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.25
EPS Estimate Next Year
0.22
EPS Estimate Current Quarter
-0.1
EPS Estimate Next Quarter
-0.04

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Artivion Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 14.34%

Current $21.06
Target $24.08

Company Financials

FY18Y/Y Change
Revenue
262.8M
↑ 38.55%
Net Income
-3.8M
↓ 202.73%
Net Profit Margin
-1.45%
↓ 3.4%
FY19Y/Y Change
Revenue
276.2M
↑ 5.09%
Net Income
1.7M
↓ 145.2%
Net Profit Margin
0.62%
↑ 2.07%
FY20Y/Y Change
Revenue
253.2M
↓ 8.32%
Net Income
-16.7M
↓ 1069.88%
Net Profit Margin
-6.59%
↓ 7.21%
FY21Y/Y Change
Revenue
298.8M
↑ 18.01%
Net Income
-14.8M
↓ 11.08%
Net Profit Margin
-4.96%
↑ 1.63%
FY22Y/Y Change
Revenue
313.8M
↑ 5.0%
Net Income
-19.2M
↑ 29.38%
Net Profit Margin
-6.12%
↓ 1.16%
FY23Y/Y Change
Revenue
354.0M
↑ 12.82%
Net Income
-30.6M
↑ 59.27%
Net Profit Margin
-8.63%
↓ 2.51%
Q3 FY22Q/Q Change
Revenue
76.8M
↓ 4.36%
Net Income
-13.7M
↑ 221.98%
Net Profit Margin
-17.85%
↓ 12.55%
Q4 FY22Q/Q Change
Revenue
79.4M
↑ 3.33%
Net Income
2.2M
↓ 115.82%
Net Profit Margin
2.73%
↑ 20.58%
Q1 FY23Q/Q Change
Revenue
83.2M
↑ 4.83%
Net Income
-13.5M
↓ 723.88%
Net Profit Margin
-16.26%
↓ 18.99%
Q2 FY23Q/Q Change
Revenue
89.3M
↑ 7.24%
Net Income
-3.4M
↓ 75.01%
Net Profit Margin
-3.79%
↑ 12.47%
Q3 FY23Q/Q Change
Revenue
87.9M
↓ 1.57%
Net Income
-9.8M
↑ 189.8%
Net Profit Margin
-11.16%
↓ 7.37%
Q4 FY23Q/Q Change
Revenue
93.7M
↑ 6.62%
Net Income
-4.0M
↓ 59.44%
Net Profit Margin
-4.24%
↑ 6.92%
FY18Y/Y Change
Total Assets
571.1M
↓ 3.48%
Total Liabilities
296.0M
↓ 5.31%
FY19Y/Y Change
Total Assets
605.7M
↑ 6.05%
Total Liabilities
320.0M
↑ 8.09%
FY20Y/Y Change
Total Assets
789.4M
↑ 30.34%
Total Liabilities
460.7M
↑ 43.98%
FY21Y/Y Change
Total Assets
793.1M
↑ 0.46%
Total Liabilities
492.3M
↑ 6.87%
FY22Y/Y Change
Total Assets
762.8M
↓ 3.81%
Total Liabilities
478.5M
↓ 2.81%
FY23Y/Y Change
Total Assets
792.4M
↑ 3.88%
Total Liabilities
510.6M
↑ 6.72%
Q3 FY22Q/Q Change
Total Assets
742.7M
↓ 2.89%
Total Liabilities
487.6M
↑ 0.88%
Q4 FY22Q/Q Change
Total Assets
762.8M
↑ 2.7%
Total Liabilities
478.5M
↓ 1.88%
Q1 FY23Q/Q Change
Total Assets
757.1M
↓ 0.75%
Total Liabilities
477.2M
↓ 0.27%
Q2 FY23Q/Q Change
Total Assets
777.9M
↑ 2.75%
Total Liabilities
495.4M
↑ 3.81%
Q3 FY23Q/Q Change
Total Assets
774.8M
↓ 0.4%
Total Liabilities
502.8M
↑ 1.51%
Q4 FY23Q/Q Change
Total Assets
792.4M
↑ 2.27%
Total Liabilities
510.6M
↑ 1.55%
FY18Y/Y Change
Operating Cash Flow
9.9M
↓ 8.53%
Investing Cash Flow
-6.7M
↓ 96.07%
Financing Cash Flow
-2.6M
↓ 101.79%
FY19Y/Y Change
Operating Cash Flow
15.8M
↑ 60.18%
Investing Cash Flow
-23.9M
↑ 256.56%
Financing Cash Flow
-1.5M
↓ 41.73%
FY20Y/Y Change
Operating Cash Flow
12.4M
↓ 21.85%
Investing Cash Flow
-73.1M
↑ 205.43%
Financing Cash Flow
93.6M
↓ 6369.79%
FY21Y/Y Change
Operating Cash Flow
-2.6M
↓ 120.9%
Investing Cash Flow
5.7M
↓ 107.74%
Financing Cash Flow
-12.2M
↓ 113.06%
FY22Y/Y Change
Operating Cash Flow
-5.2M
↑ 99.34%
Investing Cash Flow
-10.7M
↓ 289.31%
Financing Cash Flow
-1.6M
↓ 86.59%
Q3 FY22Q/Q Change
Operating Cash Flow
4.0M
↓ 147.82%
Investing Cash Flow
-3.1M
↑ 33.55%
Financing Cash Flow
252.0K
↓ 131.62%
Q4 FY22Q/Q Change
Operating Cash Flow
-217.0K
↓ 105.46%
Investing Cash Flow
-2.7M
↓ 12.61%
Financing Cash Flow
-859.0K
↓ 440.87%
Q1 FY23Q/Q Change
Operating Cash Flow
-6.2M
↑ 2735.94%
Investing Cash Flow
7.1M
↓ 365.29%
Financing Cash Flow
1.2M
↓ 236.32%
Q2 FY23Q/Q Change
Operating Cash Flow
6.9M
↓ 212.27%
Investing Cash Flow
7.1M
↑ 0.0%
Financing Cash Flow
2.2M
↑ 90.69%
Q3 FY23Q/Q Change
Operating Cash Flow
7.2M
↑ 4.68%
Investing Cash Flow
-2.1M
↓ 129.22%
Financing Cash Flow
-909.0K
↓ 140.71%

Technicals Summary

Sell

Neutral

Buy

Artivion Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Artivion Inc
Artivion Inc
3.8%
57.42%
47.69%
-12.14%
-28.2%
Stryker Corporation
Stryker Corporation
-4.59%
26.35%
10.88%
26.25%
80.99%
Boston Scientific Corp.
Boston Scientific Corp.
2.53%
35.38%
34.38%
63.21%
94.67%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-5.81%
24.49%
-1.17%
-8.62%
48.12%
Abbott Laboratories
Abbott Laboratories
-2.2%
13.48%
-2.55%
-12.23%
40.18%
Medtronic Plc
Medtronic Plc
-2.34%
12.97%
-9.37%
-37.53%
-5.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Artivion Inc
Artivion Inc
NA
NA
420.83
-0.25
-0.11
0.01
NA
6.86
Stryker Corporation
Stryker Corporation
39.67
39.67
2.92
11.85
0.18
0.07
0.01
48.92
Boston Scientific Corp.
Boston Scientific Corp.
63.57
63.57
1.8
2.25
0.09
0.04
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
38.15
38.15
5.19
2.75
0.22
0.12
NA
11.06
Abbott Laboratories
Abbott Laboratories
33.36
33.36
5.99
4.61
0.15
0.06
0.02
22.26
Medtronic Plc
Medtronic Plc
25.58
25.58
1.52
5.2
0.08
0.04
0.03
38.95
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Artivion Inc
Artivion Inc
Buy
$847.5M
-28.2%
NA
-8.67%
Stryker Corporation
Stryker Corporation
Buy
$124.7B
80.99%
39.67
15.44%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$100.0B
94.67%
63.57
11.18%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.8B
48.12%
38.15
23.36%
Abbott Laboratories
Abbott Laboratories
Buy
$185.8B
40.18%
33.36
13.96%
Medtronic Plc
Medtronic Plc
Buy
$107.0B
-5.08%
25.58
13.0%

Institutional Holdings

  • BlackRock Inc

    16.60%

  • Macquarie Group Ltd

    6.97%

  • Vanguard Group Inc

    6.38%

  • Wellington Management Company LLP

    5.97%

  • Morgan Stanley - Brokerage Accounts

    5.77%

  • Juniper Investment Co, LLC

    5.09%

Corporate Announcements

  • Artivion Inc Earnings

    Artivion Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica

Organization
Artivion Inc
Employees
1500
CEO
Mr. James Patrick Mackin
Industry
Healthcare

Discover More

FAQs